Original Research Article

Immunoprotective evaluation of Escherichia coli outer membrane protein A against the main pathogens of animal mastitis

Chen Chen¹, Nana Wu¹, Na Rong¹, Chao Kang¹, Chunlin Chen¹, Sanqiao Wu¹, Xiang Liu¹*, Xiaoying Zhang¹,²

¹Chinese-German Joint Institute for Natural Product Research/Shaanxi/Engineering Research Center for Tall Gastrodia Tuber and Medical Dogwood/College of Biological Science and Engineering, Shaanxi University of Technology, Hanzhong 723000, China, ᵇCentre of Molecular and Environmental Biology University of Minho, Department of Biology, Campus de Gualtar, Braga 4710-057, Portugal

*For correspondence: Email: liuxiang888525@163.com, zhang.xy@nwsuaf.edu.cn; Tel/Fax: +86-029-87091329, +86-0916-2641661

Sent for review: 27 September 2019 Revised accepted: 24 December 2019

Abstract

Purpose: To evaluate prokaryotic expression of the Escherichia coli (E. coli) outer membrane protein A (OmpA) and its immunoprotective function against the main pathogens of animal mastitis.

Methods: A molecular cloning method was used to develop a prokaryotic strain expressing OmpA protein, which was purified by Ni-affinity chromatography. Polyclonal antiserum was generated in mice immunized with OmpA protein. Enzyme-linked immunosorbent assay (ELISA) and western blotting were used to determine the titer and verify anti-OmpA serum specificity, respectively. Interaction between OmpA antiserum and main pathogens of animal mastitis was verified by ELISA and a pull-down method. The immune protective function of OmpA protein was evaluated in mice challenged with pathogens of animal mastitis. Optimal fermentation conditions to produce OmpA protein were determined by the L9(3⁴) orthogonal test.

Results: A prokaryotic strain expressing OmpA protein was developed, and purified OmpA was used to develop a mouse polyclonal antibody. The anti-OmpA serum exhibited high specificity and a titer of 1:1600. Anti-OmpA serum directly interacted with E. coli and Staphylococcus aureus (S. aureus). OmpA demonstrated a significant immune protective function of 58.33% against E. coli and 46.15% against S. aureus. The optimal conditions for expressing fermentation OmpA were a strain absorbance of 0.5 at a wavelength of 600 nm, IPTG final concentration of 0.3 mmol/L, induction time of 12 h, and induction temperature of 28 °C.

Conclusion: OmpA possesses selective immunogenicity and a significant immune protective effect against the main pathogens of animal mastitis. The results suggest that OmpA may potentially be used as a vaccine for animal mastitis.

Keywords: E. coli, OmpA protein, Immunoprotection, Animal mastitis, Protein fermentation

This is an Open Access article that uses a fund-ing model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

Tropical Journal of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals (DOAJ), African Journal Online, Bioline International, Open-J-Gate and Pharmacy Abstracts
INTRODUCTION

Mastitis is a common disease in the animal breeding industry, especially in cows and dairy goats [1]. Its main pathogens are E. coli, S. aureus, and Streptococcus [2,3]. Repeat infections resulting in animal mastitis occurs easily, seriously affecting milk production in cows and goats and causing huge economic losses to the dairy industry [4]. At present, the treatment for animal mastitis mainly consists of antibiotics, which inevitably leads to drug resistance, drug residues, and environmental pollution [5,6]. In addition, E. coli and S. aureus also affect human health, which are zoonotic pathogens [7]. Therefore, it is necessary to develop a new type of drug to cure animal mastitis.

Outer membrane proteins (OMPs) are the main extracellular proteins of E. coli. They play an important role in drug resistance, substance transport, immune recognition of the bacteria and host, and improve pathogenicity [8]. Outer membrane protein A (OmpA) is an important outer membrane protein of E. coli. OmpA protein has a β-barreled transmembrane structure, and is a mutual recognition protein between E. coli and host cells [9]. Thus, OmpA protein improves the pathogenicity of E. coli and is a target recognition protein of the immune system. Studies have shown that OmpA protein has a preferential immunogenicity, could activate the immune response in animals [10], and improves the ability of animals to resist bacterial infection. Taken together, these observations suggest that OmpA protein may be a good candidate for a possible vaccine.

EXPERIMENTAL

Chemicals and reagents

E. coli, S. aureus, and pET-32a plasmids were obtained from the Shaanxi University of Technology bacterial conservation center. Primer synthesis and gene sequencing were completed by the Beijing Oak Science and Technology Corp, China. Endonuclease, HRP secondary antibodies, and TMB were obtained from Sigma-Aldrich, USA.

Animals

Mice were obtained from the College of Medicine, Xian Jiaotong University, China. All animal procedures were performed in accordance with the guidelines prescribed in Guide for the Care and Use of Laboratory Animals [11] and were approved by the ethics committee of the Shaanxi University of Technology, China (approval ref no. 20170907).

Construction of prokaryotic expression strain of ompA gene

Primers for the ompA gene primers were designed based on the E. coli ompA gene sequence in the GenBank database (accession number LN832404.1): sense primer5'- CGGGAATTCATGAAAAAACAGCTATC-3'; anti-sense primer: 5'- CCAAGCTTAAAAAGCTGCGGCTGAG-3'. (The underscore represents the site of EcoR I and Hind III enzyme cleavage.) The E. coli genome was extracted using a genomic Extraction Kit (TaKaRa, Japan). The PCR system consisted of 2.5 μL buffer, 2 μL dNTP (10 mmol/L), 1.5 μL primers (25 μmol/L), 5 μL template DNA, and 0.2 μL Taq enzyme (TaKaRa, Japan). The PCR parameters consisted of 32 cycles of pre-denaturing for 3 min at 94°C, denaturing (30 s at 94°C), annealing (45 s at 55°C), and extension (90 s at 72°C), followed by full extension at 72°C for 10 min. PCR samples were separated and recovered with 0.8% agarose gel electrophoresis. After the PCR product and pET-32a plasmid vector was digested, the recombinant plasmid pET32a-ompAwas developed by ligase ligation (TaKaRa, Japan). The recombinant plasmid was identified with double enzyme digestion analysis and sequencing. Then, the recombinant plasmid of pET32a-ompA was transformed into E. coli BL21 strain to create the OmpA protein-expressing strain.

Prokaryotic expression and purification of OmpA protein

Expression and purification were performed as described previously. Briefly, OmpA recombinant strains were cultured overnight and transferred to fresh LB medium. At an OD600 Value of 0.5, IPTG was added to a final concentration of 0.5 mmol/L; the strains were then cultured at 37°C for 5 h. The expression of OmpA was assessed by SDS-PAGE electrophoresis. The OmpA protein was loaded onto a Ni-affinity chromatography column and purified using a Ni-NTA flowresin method (Sigma-Aldrich, USA) [12].

Preparation of mouse anti-OmpA polyclonal antiserum

At 4-5 weeks of age, Kunming mice were randomly selected and purified OmpA protein was intraperitoneally injected three times. The experimental and control groups were immunized with OmpA protein (50 µg per mouse) and PBS.
solution, respectively. OmpA protein and the control of PBS solution were emulsified with Freund’s Complete Adjuvant (Sigma-Aldrich, USA) for the first immunization. After 14 days, the mice were boosted using Freund’s incomplete adjuvant (Sigma-Aldrich, USA) [12]. After 7 days, a third immunization was performed. Then, the eyeballs of mice were dissected under anesthesia to harvest OmpA antiserum, which was then stored at -80°C.

**Specificity and titer detection of OmpA protein antiserum**

Specificity of OmpA antiserum was evaluated by western blot analysis. Briefly, E. coli lysates were resolved by SDS-PAGE and transferred to nitrocellulose (NC) membrane (TaKaRa, Japan) by electrotransfer. After incubation in a skim milk solution for blocking, the membrane was incubated with mouse anti-OmpA serum. Then, the membrane was incubated with horseradish peroxidase-conjugated anti-mouse secondary antibody (TaKaRa, Japan). The NC membrane was then incubated with a DAB solution (Sigma-Aldrich, USA) coloration system to visualize bands [12]. OmpA serum specificity was determined according to the color of NC membrane bands.

Antiserum titer was determined by the ELISA method. Briefly, the OmpA protein was diluted to 0.5μg/μL, and 100 μL solution was added to 96-well plate at 37°C for 3 h. After incubating in skim milk solution for blocking, 100 μL of anti-OmpA serum was added to each well and the plate was incubated at 37°C for 30 min. After rinsing, 100 μL of horseradish peroxidase-conjugated anti-mouse secondary antibody was added to each well. Then, each well was incubated with a coloration solution (Sigma-Aldrich, USA) at 37°C under dark conditions for the color reaction. Finally, a stop solution was added, and the absorption at OD450 was determined using a microplate reader (ThermoFisher Scientific, USA).

**Interaction between OmpA antiserum and pathogens of animal mastitis by ELISA and pull-down assay**

Pull-down and ELISA methods were performed as described previously. Pathogens of animal mastitis of E. coli and S. aureus were collected at logarithmic growth phase by centrifugation and washed twice with a 0.85% NaCl solution. Pathogens were inactivated and immobilized with oxymethylene at 80°C for 90 min. Then, the samples were dissolved in 0.85% NaCl and adjusted to an OD₆₀₀ of 0.2. Samples (1 mL) were transferred into 1.5 mL tubes with 10⁶ CFU bacterial cells. OmpA antiserum (100 μL) was added to each tube and 1.5 μg/μL of bovine serum albumin was used as the negative control. After rinsing, 100 μL of horseradish peroxidase-conjugated anti-mouse antiserum was added to each tube. Coloration liquid was added to every tube to avoid light reaction. After a stop solution was added to each tube, a microplate reader was used to detect the absorbance value at OD₄₅₀ [12].

**Immune protective function of OmpA protein**

SPF Kunming mice were divided to the experimental group and the control group. Briefly, purified OmpA protein (50 μg per mouse) was injected three times into the experimental group while the control group received a PBS solution. OmpA protein and the control of PBS solution were emulsified with Freund’s Complete Adjuvant (Sigma-Aldrich, USA) for the first immunization. After 14 days, the mice were boosted using Freund’s incomplete adjuvant (Sigma-Aldrich, USA). After 7 days, a third immunization was performed. Primary immunizations were performed with Freund’s complete adjuvant, while booster doses were immunized with Freund’s incomplete adjuvant. After the third immunization, mice were intraperitoneally challenged with 1.0 × 10⁸ E. coli and 1.5 × 10⁹ S. aureus, respectively. After 15 days, the relative percentage survival of mice was measured. The immune protection rates were expressed as a formula of 1 - (OmpA immunity mortality/non-OmpA immunity mortality) × 100%. The statistical software package Social Science (SPSS) was used for statistical significance analysis [11,12].

**Optimization of induced OmpA protein expression conditions**

The L₉(3⁴) orthogonal design model, which is a four-factor and three-level orthogonal design, was used to determine the optimum expression conditions of OmpA protein. The factors of orthogonal design were strain OD₆₀₀ value, IPTG final concentration, induction time, and induction temperature; these factors were represented as A, B, C, and D, respectively (Table 2). Briefly, according to the orthogonal design model, when the OD₆₀₀ concentration of OmpA expression was reached, corresponding concentrations of IPTG were added to the culture to induce OmpA protein expression with an appropriate time and temperature. One milliliter of bacterial liquid was harvested, and boiled for 5 min with 300 μL buffer solution. After centrifugation, samples (10 μL) were resolved by SDS-PAGE. G-250 dye
liquor (Sigma-Aldrich, USA) was used to visualize the OmpA protein band. Finally, Phoretix 1D software was used to analyze the optical density of OmpA protein bands, and SPSS software was used to analyze the statistical significance for each factor [12].

RESULTS

Development of a prokaryotic strain expressing OmpA protein

A fragment of approximately 1041 bp, which was consistent with the expected size, was amplified from the *E. coli* genome by PCR (Figure 1). The target gene obtained by PCR was ligated to pET-32a plasmid. The size of the target gene obtained by double enzyme digestion was consistent with the prediction (Figure 1). In addition, sequencing confirmed that the target gene was the same as the ompA gene sequence published by the NCBI database. Finally, the ompA gene recombinant plasmid was transformed into *E. coli* BL21 strain to create the OmpA protein-expressing strain.

Figure 1: PCR and restriction enzyme analysis of the *E. coli* ompA gene. M, DNA Marker. 1, PCR of the ompA gene. 2, recombinant plasmid of the ompA gene. 3, recombinant plasmid digested with EcoRI and HindIII. A fragment of approximately 1041 bp was amplified by PCR, which was consistent with the size of the ompA gene. The size of the double enzyme digestion product was consistent with the predicted recombinant gene

Prokaryotic expression and purification of OmpA protein

To verify the expression of the recombinant target protein, bacteria containing the recombinant plasmid were induced with IPTG. The presence of OmpA protein was confirmed by visualization of a 58.4 kDa protein band representing the 38 kDa OmpA protein and a 20.4 kDa fusion protein label of the pET-32a plasmid, which was consistent with the expected size (Figure 2). Purified OmpA protein was obtained with Ni-affinity chromatography (Figure 2).

![Figure 2: Prokaryotic expression and purification of OmpA protein. M, Protein marker. 1, no induction with IPTG. 2, induction with IPTG. 3, purified OmpA protein. Recombinant protein-expressing bacteria were induced with IPTG. The band corresponding to purified OmpA protein exhibited a molecular weight of approximately 58.4 kDa OmpA protein and a 20.4 kDa fusion protein. Our results demonstrate that purified OmpA protein was obtained and exhibited as one band of the expected size](image)

Specificity and titer detection of OmpA protein antiserum

Western blot analysis was used to verify the specificity of the OmpA mice antiserum. We detected a single band corresponding to the expected molecular weight of OmpA protein, indicating that the OmpA antiserum was specific (Figure 3 A). In addition, the antiserum titer of OmpA protein reached 1: 1600 with ELISA (Figure 3 B).

![Figure 3: Specificity (A) and titer (B) determination of OmpA protein antiserum. A. Western blot analysis was performed to verify the specificity of OmpA protein antiserum. Lanes 1 and 2 show results from the OmpA protein antiserum and negative control, respectively. One band was visualized, indicating that OmpA antiserum had good specificity. B. ELISA was conducted to determine the OmpA antiserum titer. As the titer increased, the OD_{450} value decreased, showing that the OmpA antiserum titer was 1:1600](image)
Interaction between OmpA antiserum and main pathogens of animal mastitis

The interaction between the OmpA antiserum and main pathogens of animal mastitis was assessed by ELISA and a pull-down method. Compared to the control group, an interaction between OmpA antiserum and E. coli was observed until a titer of 1:600 (Figure 4-A). The interaction between OmpA antiserum and S. aureus was detected up to a titer of 1:400 (Figure 4-B). These results suggest that OmpA antiserum and pathogens of animal mastitis formed antigen-antibody complexes, which likely led to antigen presentation. Thus, OmpA protein may have a preferential immunogenicity.

Figure 4: Analysis of the interaction between OmpA antiserum and the main pathogens of animal mastitis, namely E. coli (A) and S. aureus (B). As the OmpA antiserum titer increased, the OD value decreased. The interaction between OmpA antiserum and E. coli was detected up to 1:600, while interaction between OmpA antiserum and S. aureus was observed up to 1:400.

Immune protective function of OmpA protein

Mice were immunized with OmpA protein and then challenged with the enteric pathogens E. coli and S. aureus to evaluate the immunological protective effect of OmpA protein. The mice developed severe toxic symptoms, such as fluffy folds, sluggish activity, listlessness, and lethargy. Moreover, a large number died within 48 h. After 4 days, death was controlled, and the mice gradually recovered. OmpA protein demonstrated an immune protective function of 58.33% against E. coli and 46.15% against S. aureus. These results were statistically different from the control group, which was immunized with a PBS solution (Table 1).

Table 1: Active immunity of OmpA in mice following challenge with pathogens of animal mastitis

| Bacterium | OmpA | Control |
|-----------|------|---------|
| E. coli   | Nos   | Alive   | ADR (%) | RPS (%) | Nos   | Alive | ADR (%) | RPS (%) |
| S. aureus | 15    | 10     | 33.33    | 58.33*  | 15    | 3     | 80    | ----    |

ADR means accumulating death rates. RPS means relative percent survivals. RPS (%) = 1 - (OmpA immunity mortality/non-protein immunity mortality) × 100%. *P < 0.05 (compared to the control group which received PBS only)

Optimized prokaryotic expression conditions of OmpA protein

To detect the expression of OmpA protein, orthogonal design experiments were carried out. The expression map of OmpA protein was obtained by SDS-PAGE, which showed that the quantity of OmpA expression varied under different induction conditions (Figure 5). The optical density value of the OmpA protein band was obtained by Phoretix 1D software, and the range analysis was carried out (Table 2). Comparison of K1, K2, and K3 led us to determine that the optimal expression conditions of OmpA protein were A1, B2, C3, and D1, corresponding to a strain absorbance value of 0.5 at a wavelength of 600 nm, IPTG final concentration of 0.3 mmol/L, induction time of 12 h, and induction temperature of 28 °C. Variance analysis of the optical density data showed that two factors were statistically significant, including the strain absorbance value and induction time (Table 3).

Figure 5: Results from the orthogonal experiment assessing OmpA-expressing strain induced by IPTG. A, B, and C represent three independent experiments. M, Protein marker. Lane 1: non-induced strain. Lanes 2, 3, 4: strains with absorbance of 0.5, IPTG final concentration of 0.1, 0.3, and 0.5 mmol/L, induction temperature of 28, 32, and 37 °C, induction time of 3, 8, and 12 h. Lanes 5, 6, 7: strains with absorbance value of 0.8, IPTG final concentration of 0.1, 0.3, and 0.5 mmol/L, induction temperature of 37, 28, and 32 °C, induction time of 8, 12, and 3 h. Lanes 8, 9, 10: strains with absorbance value of 1.0, IPTG final concentration of 0.1, 0.3, and 0.5 mmol/L, induction temperature of 32, 37, and 28 °C, induction time of 12, 3, and 8 h.
Table 2: Optimized expression conditions for OmpA strains

| Number | A (mmol/L) | B (mmol/L) | C (h) | D (°C) | Optical density/SD (±10^{-5}) |
|--------|------------|------------|-------|--------|--------------------------------|
| 1      | 0.5        | 0.1        | 3     | 28     | 3.556 ± 0.803                  |
| 2      | 0.5        | 0.3        | 8     | 32     | 4.207 ± 0.248                  |
| 3      | 0.5        | 0.5        | 12    | 37     | 4.367 ± 0.203                  |
| 4      | 0.8        | 0.1        | 8     | 37     | 2.644 ± 0.634                  |
| 5      | 0.8        | 0.3        | 12    | 37     | 4.265 ± 1.310                  |
| 6      | 0.8        | 0.5        | 3     | 32     | 2.950 ± 0.365                  |
| 7      | 1.0        | 0.1        | 12    | 32     | 2.733 ± 0.442                  |
| 8      | 1.0        | 0.3        | 3     | 37     | 2.134 ± 0.907                  |
| 9      | 1.0        | 0.5        | 8     | 28     | 3.238 ± 0.558                  |

A, B, C, and D represent the strain OD_{600} value, IPTG induction concentration, induction time, and induction temperature, respectively. K1, K2, and K3 indicate the mean value of the analysis size, while the optimal induction expression conditions of OmpA protein are represented by A1, B2, C3, and D1.

Table 3: Variance results for OmpA protein expression

| Factor | Absorbance analysis | Mean square | F-value | P-value |
|--------|---------------------|-------------|---------|---------|
| A      | Mean square         | 4.070       | 8.467   | 0.003   |
| B      | Mean square         | 0.906       | 1.884   | 0.181   |
| C      | Mean square         | 1.858       | 3.865   | 0.040   |
| D      | Mean square         | 0.931       | 1.936   | 0.173   |

Note: A, B, C, and D represent the strain absorbance value at a wavelength of 600nm, IPTG concentration, induction time, and induction temperature, respectively. P < 0.05 was considered statistically significant compared to control group.

DISCUSSION

OmpA protein exhibits good immunogenicity, can stimulate an immune response, and has a potential application for use in a vaccine [10]. In this research, we developed an OmpA prokaryotic expression strain from which we purified OmpA protein. In addition, an anti-OmpA mouse polyclonal serum was prepared with a preferential specificity and titer of 1:1600. Compared with monoclonal antibodies, polyclonal antibodies are more convenient and economical to prepare [13,14]. Moreover, they are widely used to analyze immune function. With this study, we developed an OmpA antiserum, which laid the foundation for assessing the immunological function of OmpA protein. In this research, we found an interaction between OmpA antiserum and E. coli and S. aureus, suggesting that the anti-OmpA serum and pathogens of animal mastitis formed antigen-antibody complexes. These antigen-antibody complexes may be involved in antigen presentation, enabling easy identification by the immune system for eliminating pathogenic bacteria [15]. Thus, OmpA protein may display a selective immunogenicity. It was found that OmpA protein could activate the immune function of animals. This research showed that the immune protection of OmpA protein was significant at 58.33% against E. coli and 46.15% against S. aureus. Since E. coli, and S. aureus are the primary mastitis pathogens in cows and goats, this study lays a practical foundation for the development of an OmpA protein vaccine for animal mastitis.

The L_9 (3^4) orthogonal experimental test was used to examine the feasibility of large-scale fermentation to produce OmpA protein. We found that the optimum expression conditions for OmpA protein are an OD_{600} value of 0.5, a final IPTG concentration of 0.3 mmol/L, induction time of 12 h, and induction temperature of 28°C. Bacteria exhibit vigorous metabolism in the logarithmic growth phase, which is conducive to protein expression [16]. In this study, we found that induction of OmpA protein expression was optimal during the logarithmic growth phase. IPTG has some cytotoxicity and high concentrations can inhibit protein expression [16,17]. Consistent with this fact, our results demonstrated that a low concentration of IPTG (0.3 mmol/L) was advantageous for OmpA expression. Some research studies found that low temperature is also beneficial for protein expression [18,19], which supports our results. Thus, our data suggest that optimal fermentation production conditions involve strain induction at the logarithmic growth period, low IPTG concentration, and low temperature.

CONCLUSION

A novel prokaryotic strain expressing E. coli OmpA protein has been developed, from which OmpA protein has been purified to generate an antiserum. Optimized conditions for large-scale fermentation production of this protein have also been developed. OmpA possesses selective immunogenicity and a significant immune protection.
protective effect against the mastitis pathogens, *E. coli* and *S. aureus*. Thus, a new member has been suggested for addition to the group of vaccines used to treat animal mastitis.

**DECLARATIONS**

**Acknowledgement**

This work was supported by the High-end Foreign Experts Recruitment Program of State Administration of Foreign Experts Affairs (nos. GDT20176100048 and GDT20186100426), The Scientific Research Program of the Shaanxi Provincial Education Department (no. 17JK0137), and Project of Shaanxi University of Technology (no. SLGQD1803).

**Conflict of interest**

No conflict of interest is associated with this work.

**Contribution of authors**

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors.

**Open Access**

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/resolve), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

**REFERENCES**

1. Petersson-Wolle CS, Leslie KE, Swartz TH. An update on the effect of clinical mastitis on the welfare of dairy cows and potential therapies. Vet Clin North Am Food Anim Pract 2018; 34(3): 525-535.

2. Heikilä AM, Liiski E, Pyörälä S, Taponen S. Pathogen-specific production losses in bovine mastitis. J Dairy Sci 2018; 101(10): 9493-9504.

3. Saidani M, Messadi L, Soudani A, Daaloul-Jedidi M, Châtre P, Ben Chehida F, Mamlouk A, Mahjour W, Madec JY, Haenni M. Epidemiology, antimicrobial resistance, and extended-spectrum Beta-lactamase-producing enterobacteriaceae in clinical bovine mastitis in Tunisia. Microb Drug Resisit 2018; 24(8): 1242-1248.

4. Kawai K, Shizozuka Y, Uchida I, Hirose K, Mitamura T, Watanabe A, Kuruhara K, Yuasa R, Sato R, Onda K. Control of *Pseudomonas* mastitis on a large dairy farm by using slightly acidic electrolyzed water. Anim Sci J 2017; 88(10): 1601-1605.

5. Damm M, Holm C, Blaabjerg M, Bro MN, Schwarz D. Differential somatic cell count-A novel method for routine mastitis screening in the frame of Dairy Herd Improvement testing programs. J Dairy Sci 2017; 100(6): 4926-4940.

6. Shoyele O, Vdhun R, Dodge J, Cheng Z, Margules R, Tee P, Sieber S. Cystic neutrophilic granulomatous mastitis: A clinicopathologic study of a distinct entity with supporting evidence of a role for *Corynebacterium*-targeted therapy. Ann Diagn Pathol 2018; 37: 51-56.

7. Zi C, Zeng D, Ling N, Dai J, Xue F, Jiang Y, Li B. An improved assay for rapid detection of viable *Staphylococcus aureus* cells by incorporating surfactant and PMA treatments in qPCR. BMC Microbiol 2018; 18(1): 132.

8. Ebbensgaard A, Mordhorst H, Aarestrup FM, Hansen EB. The role of outer membrane proteins and lipopolysaccharides for the sensitivity of *Escherichia coli* to antimicrobial peptides. Front Microbiol 2018; 9: 2153.

9. Novinrooz A, Zahraei Salehi T, Firoozi R, Arbashahi S, Derakhshande A. In-silico design, expression, and purification of novel chimeric *Escherichia coli* O157:H7 OmpA fused to LTβ protein in *Escherichia coli*. PLoS One 2017; 12(3): e0173761.

10. Kudva IT, Krastins B, Torres AG, Griffin RW, Sheng H, Sarracino DA, Hovde C, Caldenwood SB, John M. The *Escherichia coli* O157:H7 cattle immunoproteome includes outer membrane protein A (OmpA), a modulator of adherence to bovine rectoanl junction squamous epithelial (RSE) cells. Proteomics 2015; 15(11): 1829-1842.

11. Guide for care and use of laboratory animals. National Academy of Sciences Committee for the Update of the Guide for the Care and Use of Laboratory Animals, the National Academies Press, 8th edn. 2011.

12. Liu X, Chen C, Chen C, Ding R, Marslin G. Construction of a recombinant OmpC dominant epitope-based vaccine against *Escherichia coli* and evaluation of its immunogenicity and protective immunity. Jundishapur J Microb 2017; 10(11): e55652.

13. Liu X, Yang MJ, Wang SN, Xu D, Li H, Peng XX. Differential antibody responses to outer membrane proteins contribute to differential immune protections between live and inactivated *Vibrio parahaemolyticus*. J proteome Res 2018; 17(9): 2987-2994.

14. Zhang C, Huang X, Chen S, Li Y, Li Y, Wang X. Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid. Vaccine 2018; 18: 31295-31297.

15. Zhao J, Nussinov R, Ma B. Antigen binding allosterically promotes Fc receptor recognition. MAbs 2018; 13:1-17.
16. Liu X, Chen C, Marslin G, Ding R, Wu SQ. Construction and evaluation of a novel triple cell epitope-based polypeptide vaccine against cow mastitis induced by Staphylococcus aureus, Escherichia coli and Streptococcus. Trop J Pharm Res 2017; 16(10): 2477-2486.

17. Ghaderi H, Arasteh J, Hesampour A. Using response surface methodology in combination with Plackett-Burman design for optimization of culture media and extracellular expression of Trichoderma reesei synthetic endoglucanase II in Escherichia coli. Mol Biol Rep. 2018; 45(5): 1197-1208.

18. Lotfi H, Hejazi MA, Heshmati MK, Mohammadi SA, Zarghami N. Optimizing expression of antiviral cyanovirin-N homology gene using response surface methodology and protein structure prediction. Cell Mol Biol (Noisy-le-grand). 2017; 63(9):96-105.

19. Pham N, Dao N, Saviola B. Over expression of the constitutive expression refractory Mycobacterium tuberculosis Rv3488 protein with an acid-inducible expression system. J Microbiol Method 2018; 18: 30283-30285.